Recently Viewed
Clear All$2.24
$-0.07
(-3.03%)
As on 02-Apr-2026 16:35EDT
Today’s Range
52 Week Range
Liquidity
Market cap
$295 Mln
Revenue (TTM)
$564 Mln
Net Profit (TTM)
$0 Mln
ROE
0.1 %
ROCE
-- %
P/E Ratio
15.3
P/B Ratio
1
Industry P/E
--
EV/EBITDA
5.2
Div. Yield
0 %
Debt to Equity
0.3
Book Value
$3.3
EPS
$0.3
Face value
--
Shares outstanding
128,640,671
CFO
$18.95 Mln
EBITDA
$138.98 Mln
Net Profit
$24.30 Mln
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Organogenesis Holdings Inc. Class A (ORGO)
| -56.8 | -30.2 | -56.8 | -47.7 | 1.7 | -35.3 | -- |
|
BSE Sensex
| -13.4 | -9.8 | -13.9 | -3.6 | 7.5 | 7.9 | 11.2 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
2020
|
|---|---|---|---|---|---|---|
|
Organogenesis Holdings Inc. Class A (ORGO)
| 61.9 | -21.6 | 52.0 | -70.9 | 22.7 | 56.5 |
|
S&P Small-Cap 600
| 4.0 | 7.0 | 13.9 | -17.4 | 25.3 | 9.6 |
|
BSE Sensex
| 9.1 | 8.1 | 18.7 | 4.4 | 22.0 | 15.8 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Organogenesis Holdings Inc. Class A (ORGO)
|
2.2 | 294.6 | 564.2 | 37.0 | 10.0 | 9 | 15.3 | 1.0 |
| 61.0 | 8,072.9 | 1,091.0 | 202.3 | 31.6 | 31.3 | 36 | 14.2 | |
| 229.3 | 13,405.2 | 691.7 | -219.0 | -13.7 | 163.2 | -- | 14.6 | |
| 66.7 | 7,755.6 | 88.0 | -785.0 | -808.1 | 197.5 | -- | 60.3 | |
| 43.9 | 11,247.3 | 2,320.1 | 782.6 | 39.0 | 35.5 | 14.9 | 5.0 | |
| 93.8 | 11,306.9 | 982.0 | -416.3 | -42.1 | 348.4 | -- | 55.7 | |
| 546.9 | 11,592.5 | 958.4 | -288.3 | -27.8 | -42.5 | -- | 16.8 | |
| 498.3 | 13,063.9 | 2,530.2 | 451.1 | 21.3 | 70.2 | 30.1 | 28.0 | |
| 105.4 | 7,603.8 | 0.0 | -425.4 | -- | -36.7 | -- | 6.0 | |
| 310.4 | 7,699.1 | 0.0 | -303.3 | -- | -45.8 | -- | 8.8 |
Organogenesis Holdings Inc., a regenerative medicine company, develops, manufactures, and commercializes products for the advanced wound care, and surgical and sports medicine markets in the United States. Its advanced wound care products include... Affinity and Novachor, which are amnion and chorion placental allografts for use in the care of chronic and acute wounds as protective barriers and extracellular matrix (ECM) scaffolds; Apligraf, a bioengineered bi-layered skin substitute for the treatment of venous leg ulcers and diabetic foot ulcers (DFU); Dermagraft, a dermal substitute grown from human dermal fibroblasts to treat DFUs; NuShield, a dehydrated placental allograft and surgical barrier to provide a protective barrier and ECM scaffold to support native healing; PuraPly Antimicrobial (AM) and PuraPly SX, which are antimicrobial barriers for the management of open wounds in surgical settings; and CYGNUS Dual, VIA Matrix, and SimpliMax are placental tissue grafts used to treat chronic and acute wounds that can be stored at room temperature. The company also provides PuraPly MZ, a micronized version of PuraPly for the management of open wounds in surgical settings; PuraForce, a bioengineered porcine collagen surgical matrix for use in soft tissue reinforcement applications; FortiShield, a biosynthetic wound matrix for use as a temporary protective covering; and TransCyte, a bioengineered tissue scaffold that promotes burn healing. In addition, it develops ReNu, a cryopreserved suspension, which is in Phase 3 trial, for the management of symptoms associated with knee osteoarthritis; and placental products. The company serves hospitals, wound care centers, government facilities, ambulatory service centers, and physician offices through direct sales representatives and independent agencies. Organogenesis Holdings Inc. is headquartered in Canton, Massachusetts. Address: 85 Dan Road, Canton, MA, United States, 02021 Read more
President, CEO, Chair of the Board
Mr. Gary S. Gillheeney Sr.
President, CEO, Chair of the Board
Mr. Gary S. Gillheeney Sr.
Headquarters
Canton, MA
Website
Our rating system has guided millions of investors in the past 20 years.
The share price of Organogenesis Holdings Inc Class A (ORGO) is $2.24 (NASDAQ) as of 02-Apr-2026 16:35 EDT. Organogenesis Holdings Inc Class A (ORGO) has given a return of 1.69% in the last 3 years.
The P/E ratio of Organogenesis Holdings Inc Class A (ORGO) is 15.27 times as on 31-Mar-2026.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2025
|
18.49
|
1.58
|
|
2024
|
491.20
|
1.10
|
|
2023
|
109.06
|
1.94
|
|
2022
|
22.84
|
1.34
|
|
2021
|
13.08
|
5.11
|
The 52-week high and low of Organogenesis Holdings Inc Class A (ORGO) are Rs 7.08 and Rs 2.21 as of 04-Apr-2026.
Organogenesis Holdings Inc Class A (ORGO) has a market capitalisation of $ 295 Mln as on 31-Mar-2026. As per SEBI classification, it is a Small Cap company.
Before investing in Organogenesis Holdings Inc Class A (ORGO), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.